Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

ADTs, including selective serotonin reuptake inhibitors (SSRIs): Lexapro(R) (escitalopram), Prozac(R) (fluoxetine), Paxil CR(R) (paroxetine controlled-release), Zoloft(R) (sertraline); or a serotonin-norepinephrine reuptake inhibitor (SNRI): Effexor XR(R) (venlafaxine extended release). The dosage range for adjunctive ABILIFY was 2-20 mg/day (15 mg/day was the maximum dose for patients receiving ABILIFY as an adjunct to Paxil CR or Prozac).

The primary efficacy endpoint was the mean change from baseline -- the end of the prospective treatment phase -- to the end of the randomized treatment phase in a standard measure called Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale used to assess depressive symptoms. A reduction in MADRS Total Score represents an improvement in depressive symptoms. The key secondary endpoint was the Sheehan Disability Scale (SDS), a three-item self-rated instrument used to assess the impact of depression on three domains of functioning (work/school, social life and family life) with each item scored from zero (not at all) to 10 (extreme). Safety evaluations included incidence of adverse reactions, discontinuation rate due to adverse reactions and laboratory measures.

For the primary endpoint, both studies showed that taking ABILIFY plus an ADT provided superior improvement in depressive symptoms to ADT alone at study endpoint (week six), as measured by the reduction of the MADRS Total Scores.(3) For the secondary endpoint, ABILIFY plus an ADT was also superior to placebo plus ADT in reducing the mean SDS Total Score in one study.

In these studies, adjunctive ABILIFY demonstrated no clinically important differences on metabolic parameters, including prolactin, fasting glucose, HDL, LDL and total cholesterol. The median percent change from baseline in triglycerides was 5 percent for adjunctive ABILIFY-treated patients vs 0 percent for adjunctive placebo-treated patients. In the studies, weight
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... With recent advancements in residential solar power ... companies are getting into the Solar Energy wave. ... renewable energy production, many homeowners are looking to residential ... a new solar distribution company in California which has ... homeowners to enjoy the benefits of solar energy without ...
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... leadership consulting and culture shaping worldwide, ... firm to lead its global Healthcare and Life Sciences practice. ... Life Sciences, Mitchell will lead a team of more than ... Europe and Asia serving ...
(Date:3/30/2015)... , March 30, 2015 US-Australian drug ... and its subsidiary, CanTx, Inc., and Yale University, on ... Cantrixil. The data was presented as an oral presentation ... Yale Medical School to the 62 nd Annual ... San Francisco, CA. ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
Breaking Biology Technology:Solara Power Announces Residential Solar Power with No Up-Front Fees 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... 27, 2008 - Vol. 299. No. 8: ,Venous Thromboembolism ... Administration for the Treatment of ... Biotech believes that,the conclusions of a study published in ... American Medical Association (JAMA) by Bennett, et al, do,not ...
... Colo., Feb. 26 Replidyne, Inc.,(Nasdaq: RDYN ) today ... ended December 31, 2007., Replidyne reported a net loss ... or a net loss per basic and diluted common share,of ... million, or $0.36 per,basic and diluted common share, for the ...
... Firms Recommend Pharmion ... merger with Celgene Special Meeting ... Corp. Urges All Shareholders to Vote FOR the Proposed Merger, ... ) today announced that Institutional Shareholder Services,(ISS) has recommended that ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... a new location or go extinct as a result of ... Northern England seem to defy the odds and adapt to ... study by scientists from Syracuse University and the University of ... of the Early Edition of the Proceedings of the ...
... -- The Soil Science Society of America (SSSA) applauds ... his colleagues in the Senate who helped usher in ... placing soil on par with water and air. ... Senators Kent Conrad (D-ND), Charles Grassley (R-IA), Russ Feingold ...
... lenses are joining the trend to go green. Chemical ... fluid found in our bodies can be used as a ... step up from the current wave of self-moisturizing contact lenses ... eye dryness and increase wearer comfort. It is estimated ...
Cached Biology News:New study finds that some plants can adapt to widespread climate change 2Senate resolution shines spotlight on the importance of soils 2Self-moisturizing contact lenses, naturally 2
... against Nonmuscle Myosin II Heavy Chain ... in TBS + 0.03% Thimerosal) This ... SDVNETQPPQSE corresponding to the C-terminus of ... (MHC-B) This antibody is effective in ...
... Factor XIII in both reduced and non-reduced forms. ... B-chain or human Factor XII. Factor XIII is ... of two subunits. Factor XIII-A is the catalytic ... Factor XIII is present in plasma as an ...
... 'The DNAscope V is a ... microarray scanning and image processing that deliver ... V is a high quality microarray scanner ... imaging technology for optimal background rejection and ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... NaCl, 10 mM sodium HEPES, ... pH 7.5. Recognizes the ~47 ... 2 (MAPKAPK-2) protein phosphorylated at ...
Biology Products: